An electrogenerated chemiluminescence (ECL) sensor for the determination of propranolol hydrochloride was fabricated by employing tris(2,2'-bipyridyl)ruthenium(II) (Ru(bpy)32+) as an ECL signal producer and graphene as a modified material. The ECL sensor was fabricated by adsorbing Ru(bpy)32+ onto a mixture of graphene and Nafion. The introduction of conductive graphene into Nafion was found to greatly enhance the ECL intensity of Ru(bpy)32+ and the ECL intensity of Ru(bpy)32+ decreased in the presence of propranolol hydrochloride. Based on this phenomenon, a sensitive and stable ECL method was developed for the determination of propranolol hydrochloride by employing a Ru(bpy)32+-graphene-Nafion modified electrode. Under the optimized conditions, the ECL intensity was linear with the concentration of propranolol hydrochloride over a range of 1.0 × 10-10 to 5.0 × 10-9 mol L-1 with a detection limit of 3 × 10-11 mol L-1. The ECL sensor exhibited long-term stability with a relative standard deviation of 4.1% for sixteen continuous determinations of 2.0 × 10-9 mol L-1 propranolol hydrochloride. The developed method has been successfully applied to the determination of propranolol hydrochloride in pharmaceutical samples.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: